Cerebral edema

Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease

Retrieved on: 
onsdag, april 27, 2022
Cell death, Amnesia, Amyloid, U.S. Securities and Exchange Commission, Pathology, Security (finance), NASDAQ, Research, Synapse, Neuron, Private Securities Litigation Reform Act, GLOBE, Patient, Goal, ABOS, AD, Plaque, Cerebral edema, SEC, Safety, Frontiers, Neurodegeneration, Dementia, Therapy, ARIA, Pharmaceutical industry, Acumen, Neuroscience

The article is titled ACU193: An immunotherapeutic poised to test the amyloid oligomer hypothesis of Alzheimers disease and can be accessed here .

Key Points: 
  • The article is titled ACU193: An immunotherapeutic poised to test the amyloid oligomer hypothesis of Alzheimers disease and can be accessed here .
  • Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimers disease.
  • Acumens scientific founders pioneered research on AOs, which a growing body of evidence indicates are primary triggers of Alzheimers disease pathology.
  • Additional information will be made available in other filings that Acumen makes from time to time with the SEC.

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

Retrieved on: 
tisdag, april 19, 2022
Cell death, Disability, U.S. Securities and Exchange Commission, Atopic dermatitis, Cerebral edema, Stroke, Lists of diseases, NASDAQ, Alzheimer's disease, Stress (linguistics), Annual report, Caregiver, Oxidative stress, Private Securities Litigation Reform Act, Military personnel, Brain, Organization, Anaphylaxis, Mast cell activation syndrome, Risk, Death, Patient, Inflammation, Health, Disease, TBI, Traumatic brain injury, Quality of life, Emergency, Therapy, Pharmaceutical industry, Hoth, Coronavirus

NEW YORK, April 19, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth. HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI"). HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.

Key Points: 
  • HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g., brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury ("TBI").
  • TBIs occur due to physical or mechanical trauma to the brain but are also associated with secondary brain injury (e.g., fluid/swelling, inflammation, oxidative damage, etc.).
  • The statistics of patients permanently impacted by stroke and TBI is astounding and Hoth is driven to reduce that burden."
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

Global Proliferative Diabetic Retinopathy Market (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
torsdag, april 14, 2022
Diabetes, Pharmaceutical, Health, Center, Korea Disease Control and Prevention Agency, Severe cognitive impairment, Eye, Risk, Retinopathy, Visual acuity, Diabetes, Columbia University, Patient, Retina, Growth, The International Agency for the Prevention of Blindness, Optic disc, Visual impairment, PDR, Organic, Diabetic retinopathy, Primate experiments at Columbia University, Blood, Cerebral edema, Prevalence, Pharmaceutical industry

Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina.

Key Points: 
  • Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina.
  • Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).
  • North America is expected to hold a major market share in the global proliferative diabetic retinopathy market due to rising prevalence of diabetes and diabetic retinopathy and availability of advanced technology and minimally invasive laser technique in this region.
  • According to the Centers for Disease Control and Prevention, approximately 4.2 million adults had diabetic retinopathy and 655,000 had vision-threatening diabetic retinopathy.

Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio

Retrieved on: 
torsdag, april 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, NDA, Ageing, Amyloid, Pathology, Cerebral edema, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Alzheimer's disease, MD, Food, Brain, Neurotoxicity, Doctor of Philosophy, Biomarker, Technology, Genotype, AD, Plaque, National Institute, APOE4, Safety, Fast Track, Disease, Risk, Neurodegeneration, Dementia, National Institute on Aging, Pharmaceutical industry, Medical imaging, Alzheon

In mechanism of action studies, ALZ-801 has been shown to fully inhibit the formation of amyloid oligomers at the Phase 3 clinical dose.

Key Points: 
  • In mechanism of action studies, ALZ-801 has been shown to fully inhibit the formation of amyloid oligomers at the Phase 3 clinical dose.
  • The APOLLOE4 trial is supported by a $47 million grant from the National Institute on Aging .
  • Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease and other neurodegenerative disorders.
  • ALZ-801is an oral small molecule that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain.

Donisi Health Presents Data at ACC22 Demonstrating Accuracy of a Contact-Free Medical Device that Detects Pulmonary Congestion in CHF Patients at Home

Retrieved on: 
måndag, april 4, 2022
Biomarker, Interventional cardiology, American College of Cardiology, Cardiology, Trial of the century, Tel Aviv Sourasky Medical Center, Research, Health, Respiratory rate, CHF, Pulmonary edema, Technology, Safety, Congestion, Medtech, American College, Heart rate, TEL, Physician, Medicare, Cerebral edema, Heart, Department, FDA, Weight gain, AI, Patient, Pharmaceutical industry, Medicine, Medical imaging, Medical device

Pulmonary congestion, the buildup of liquid in the tissue and air spaces in the lungs, is a key indicator of CHF exacerbation.

Key Points: 
  • Pulmonary congestion, the buildup of liquid in the tissue and air spaces in the lungs, is a key indicator of CHF exacerbation.
  • Today there are no easy-to-use at home tools that provide early detection of pulmonary congestion to help physicians prevent hospitalizations of CHF patients.
  • Of the study participants, 101 suffered from pulmonary congestion, and the other 126 participants were patients without congestion who served as study controls.
  • Donisi has the only clinically validated contact-free technology that can remotely detect signs of pulmonary congestion and additional bio-parameters in the home.

Sterile Compounding Pharmacies Market Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
tisdag, mars 22, 2022
Health, Pharmaceutical, Risk, CAGR, Pharmacy, Rheumatology, Cerebral edema, Gastroenterology, Growth, Food and Drug Administration Modernization Act of 1997, National Association, Mannitol, Fentanyl, Dermatology, Food, Pharmacist, Adalimumab, NABP, Board, Hydromorphone, FDA, Patient, Sterilization, National Association of Boards of Pharmacy, IV, Medical device, Pharmaceutical industry, Midazolam

The "Sterile Compounding Pharmacies Market Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sterile Compounding Pharmacies Market Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The sterile compounding pharmacies market is projected to reach US$ 6,198.59 million by 2028 from US$ 3,968.70 million in 2021; it is expected to grow at a CAGR of 6.6% from 2021 to 2028.
  • On-site sterile compounding has gained significant attention in the market and is one of the most impacting factors responsible for the market growth.
  • Such factors would support the growth of the sterile compounding pharmacies market for the intravenous segment during the forecast period.

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

Retrieved on: 
tisdag, mars 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Risk, NDA, Diagnosis, Neurotoxicity, Ageing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Oral, Reverse-path forwarding, Plasma, Biomarker, Science, AD, Food, Alzheimer's disease, Doctor of Philosophy, Safety, Lists of diseases, Neurodegeneration, Cerebral edema, Program, New Drug Application, Precision medicine, Plaque, Fast Track, Disease, Conference, CEO, Maintenance, National Institute, National Institute on Aging, Technology, Brain, International Conference on Emerging Infectious Diseases, MD, Pathology, Pharmaceutical industry, Medical imaging, Alzheon, APOE4

This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.

Key Points: 
  • This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.
  • At the NDDS conference, Dr. John Hey, Chief Scientific Officer of Alzheon and Alzheon CEO, Dr. Martin Tolar will give oral presentations on Tuesday, March 29, 2022, at 12:30 p.m.
  • This is a double-blind, randomized trial comparing one dose of oral ALZ-801 to placebo treatment over 78 weeks.
  • Our lead Alzheimers clinical candidate, ALZ-801 , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.

Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access

Retrieved on: 
torsdag, mars 3, 2022
Marketing, Terminology, PHSA, Ophthalmology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Leadership, Patient, BLA, Mab, Risk, Food, Eye, VEGF, Retinal, SVP, Annual report, Biologics license application, Security (finance), U.S. Securities and Exchange Commission, FDA, Growth, Therapy, Bleeding, Blood, Retina, Goal, SEC, BRVO, COVID-19, Senior, AMD, Bevacizumab, Anti–vascular endothelial growth factor therapy, Cerebral edema, DME, Diosynth, Physician, Nasdaq, GLOBE, Pharmaceutical industry, Outlook, Genentech

ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access.

Key Points: 
  • ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Alicia Tozier has been appointed as Senior Vice President, Marketing and Market Access.
  • Ms. Tozier is a proven global commercialization leader with expertise across nine ophthalmology disease areas, and she has launched combination products spanning multiple modalities including medical devices, digital therapeutics and pharmaceuticals.
  • She will be responsible for leading the global commercial strategy, including marketing and market access, to ensure launch readiness across customers and channels.
  • In her role as SVP, Marketing and Market Access at Outlook Therapeutics, Ms. Tozier will report directly to Chief Commercial Officer Mr. Evanson and work cross-functionally with the leadership team.

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Retrieved on: 
fredag, februari 18, 2022
Research, Radiology, Pharmaceutical, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Nursing, Other Technology, Health, Other Science, Pneumonitis, Medicine, Lung cancer, Electronics, Death, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, DDR, Entrepreneurship, Royal commission, The New England Journal of Medicine, AST, European, ALT, Edema, Merck Serono, Phase, Diarrhea, Cerebral edema, Health care, Neoplasm, Creatinine, Diagnosis, Merck Millipore, Netherlands Cancer Institute, Government, ILD, Health, Review, Large-cell lung carcinoma, Gene editing, Hypoalbuminemia, Interstitial lung disease, EU, Cancer, Policy, NSCLC, EGFR, EC, Patient, Food, Science, Immunotherapy, MET, QT interval, Phase II, Nausea, Intelligence, Toxicity, Pharmaceutical industry, Medical imaging, Merck, the VISION Study, TEPMETKO® (tepotinib), Merck, THE VISION STUDY, TEPMETKO® (TEPOTINIB), MERCK

The approval of TEPMETKO provides a much-needed targeted treatment option for patients with advanced non-small cell lung cancer with METex14 skipping alterations, said Professor Egbert Smit, a VISION study investigator at the Netherlands Cancer Institute.

Key Points: 
  • The approval of TEPMETKO provides a much-needed targeted treatment option for patients with advanced non-small cell lung cancer with METex14 skipping alterations, said Professor Egbert Smit, a VISION study investigator at the Netherlands Cancer Institute.
  • TEPMETKO has demonstrated durable and consistent response rates and has the potential to significantly help patients with this challenging cancer.
  • The approval is based on results from the pivotal Phase II VISION study evaluating TEPMETKO as monotherapy in patients with advanced NSCLC with METex14 skipping alterations.
  • Based on the 01 February 2021 data cut, 275 patients with a median age of 72.6 years with advanced or metastatic NSCLC with METex14 skipping alterations have been analyzed.

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

Retrieved on: 
tisdag, februari 8, 2022
Diosynth, Retinal, GLOBE, Senior, Growth, Blood, Eye, U.S. Securities and Exchange Commission, Biologics license application, Solution, PHSA, Terminology, Bevacizumab, SVP, Marketing, Bleeding, Annual report, Therapy, FDA, Patient, Retina, Anti–vascular endothelial growth factor therapy, GPO, BLA, Security (finance), VEGF, HUB, DME, SEC, Risk, Mab, Cerebral edema, Physician, AmerisourceBergen, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Food, Commercial Operating System (COS), AMD, Business development, BRVO, Group purchasing organization, COVID-19, Pharmaceutical industry, Fine chemical, Outlook

ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.

Key Points: 
  • ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
  • Outlook Therapeutics is thrilled to welcome Joel to our executive leadership team.
  • Mr. Prieve added, I am delighted to join Outlook Therapeutics at such an important stage of its development.
  • I look forward to working with Jeff and the rest of the team on the potential commercial launch of ONS-5010.